Dr. Keith Cengel, pleural mesothelioma specialist

Keith Cengel

Executive Director, Mesothelioma and Pleural Diseases Program

Dr. Keith Cengel is the executive director of Penn Medicine’s Mesothelioma and Pleural Diseases Program, which includes an all-encompassing, multidisciplinary approach to treatment.

Get in touch

About Keith Cengel

Accolades
  • Pleural and Lung Cancer icon

    Pleural and Lung Cancer

  • Team Leader icon

    Team Leader

  • Works for Specialty Center icon

    Works for Specialty Center

  • Research Excellence icon

    Excellence in Research

  • Board Certified icon

    Board Certified in Radiation Oncology

In addition to the Mesothelioma and Pleural Diseases Program, Cengel also is director of the Photodynamic Therapy Program, a key component in the care of patients with pleural mesothelioma at the Abramson Cancer Center.

The Mesothelioma Program brings together specialists in medical, surgical and radiation oncology. The team meets weekly to discuss each case, making sure every patient receives the best care possible.

“We are one of the only centers in the world with this kind of expertise,” Cengel said. “We are treating patients with the most modern therapies, moving from bench to the bedside to bring hope to a disease like mesothelioma, where there has not been much hope and promise in the past.”

The program includes pulmonologists with extensive experience in diagnosing various lung diseases and pathologists who specialize in evaluating lung tissue.

It also conducts clinical trials exploring the latest immunotherapy advancements.

As a radiation oncologist, Cengel has expertise treating mesothelioma, lung cancer, thymus cancer, neuroendocrine tumors and thymic carcinoma. He is skilled in the use of proton and photodynamic therapy.

He serves as an associate professor of radiation oncology at the hospital of the University of Pennsylvania.

He also runs the Cengel Laboratory, which focuses on therapeutic advancements and finding the optimal balance between killing cancer cells and minimizing damage to normal cells and tissue.

Leading Research on Photodynamic Therapy

Cengel is the lead investigator in a clinical trial investigating the use of photodynamic therapy with lung-sparing pleurectomy/decortication surgery for mesothelioma patients.

Photodynamic therapy involves sensitizing cancer cells to light with medication and then killing the cancer with low-level light beams. Penn Medicine was one of the first programs to use it for thoracic diseases.

“In addition to unique treatment options for front-line therapy, we also have unique resources to use if the tumors come back,” Cengel said. “This includes the most modern radiotherapy, as well our proton center.”

The Proton Therapy Center is the largest and most advanced facility of its kind in the world, and the only one fully integrated with a National Cancer Institute-designated cancer center.

Cengel earned his degree at the University of Illinois School of Medicine. He did his first residency at the University of Illinois and his second at the University of Pennsylvania.

He also is a cancer survivor, which has given him a real passion for what he does.

“My treatment philosophy is to walk by the patient’s side for every step of this difficult journey,” he said. “I draw from personal experience. I know what it’s like to be sitting on the other side.”

Disclaimer: Dr. Keith Cengel has no professional affiliation with Asbestos.com.

stethoscope icon
Get Help Contacting this Doctor

We value your privacy. By submitting, you agree to our privacy policy and disclaimer.

Get the Best Treatment Options

Find a Doctor
Asbestos.com Mesothelioma Packet

Order Your Free Treatment Guide

Get Yours Now

Find a Mesothelioma Clinical Trial Near You

Get Help Now

Senior Content Writer

Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers.

Daniel King, Content Writer for Asbestos.com
Edited by

2 Cited Article Sources

  1. Penn Medicine (n.d.). Keith Cengel, MD, PhD.
    Retrieved from: https://www.pennmedicine.org/providers/profile/keith-cengel?fadf=pennmedicine
  2. Perelman School of Medicine University of Pennsylvania. (n.d.). Cengel Lab. # Retrieved from: http://www.xrt.upenn.edu/CengelLab.html
  •  
  •  
  •  

Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

On This Page

Back to Top

Share this article

Last Modified August 28, 2019

Get Your Free Mesothelioma Guide Chat live with a patient advocate now